tag:blogger.com,1999:blog-4241416962008169508.post5371768419377596436..comments2024-03-29T06:40:19.495-04:00Comments on Just A Life Sciences Blog...: Come 2016 Or So, Merck's MK-5172 Is Likely To Cannibalize Some Of Merck's Victrelis® Sales -- But Not Vertex's Incivek® Sales Unknownnoreply@blogger.comBlogger5125tag:blogger.com,1999:blog-4241416962008169508.post-77928500137820673162013-04-24T17:43:05.830-04:002013-04-24T17:43:05.830-04:00Spot on! The NS5b nucleoside inhibitor that Gilead...Spot on! The NS5b nucleoside inhibitor that Gilead obtained from Pharamasett is going to be hard to beat. Its use in combination with the NS5a inhibitor from BMS gave spectacular results. However, by itself, or in combination with what Gilead has in-house, the results are less impressive. All to say that, yes, with so many exciting compounds reaching the end of their clinical development cycle, it is hard to see a scenario where Merck would get a bigger slice of the HCV market than they have now at the moment.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-71783362607270156152013-04-24T00:04:40.254-04:002013-04-24T00:04:40.254-04:00My post is up. Do let me know what you think.
Nam...My <a href="http://shearlingsplowed.blogspot.com/2013/04/okay-trivial-pursuit-will-real-mk-5172.html" rel="nofollow">post is up</a>. Do let me know what you think.<br /><br />NamasteCondorhttp://shearlingsplowed.blogspot.comnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-70042047861392660292013-04-23T23:46:02.737-04:002013-04-23T23:46:02.737-04:00Okay -- take a look here -- and at the new post.
...Okay -- take <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=162108841&viewopt=PubChem" rel="nofollow">a look here</a> -- and at the new post.<br /><br />I think mine matches PubChem.<br /><br />I guess it is possible that PubChem's is wrong. But that seems unlikely -- I've shown it as a simple line drawing, in my graphic in the next post, to make the comparison easier. Thoughts?<br /><br />NamasteCondorhttp://shearlingsplowed.blogspot.comnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-54461700803319304122013-04-23T23:20:21.241-04:002013-04-23T23:20:21.241-04:00I hear you, Anon. -- and thanks for the chemistry ...I hear you, Anon. -- and thanks for the chemistry lesson(!).<br /><br />My point was more that in the presnetly-approved FDA regimens, Incivek is king.<br /><br />MK-5172 is a good candidate -- but it looks to me as though Gilead's next gen Hep C candiate will be on the market for close to a year and a half, before MK-5172 reaches an FDA filing date. It is likely to obsoleted by the Gilead candidate, which is two years ahead of it, in the development cylce. That is the way I should have laid out my point -- more preciseley -- above.<br /><br />So -- in my opinion, the next one and a half years belong to Vertex, and the next four or so look to belong to Gilead -- in the Hep C market in the US, at least.<br /><br />As ever, we shall see. Do stop back; and thanks for commenting. Now, as to your opening observation on chemical structures, I'm going to go check the PubChem database, to see what it shows as the final molecule for MK-5172. Presumably, Merck itself submitted that model to the database. And I guess I'll trust that they MRL knows what it is they are making, and testing, here.<br /><br />Namaste, friend!<br />Condorhttp://shearlingsplowed.blogspot.comnoreply@blogger.comtag:blogger.com,1999:blog-4241416962008169508.post-44024181362460873092013-04-23T20:32:08.530-04:002013-04-23T20:32:08.530-04:00The structure you have for MK5172 is not correct (...The structure you have for MK5172 is not correct (the structure you have drawn, the acid, is the starting material for the last step) and should instead be an acylsulfonamide. Furthermore, although I agree with your assessment that MK5172 may not be a game changer in the HCV field, but it won't be because Incivek is a great compound (MK5172 is vastly superior in terms of both potency as well as genotype and mutant coverage) but because most of the HCV patients will already be well served by the time MK5172 is on the market.Anonymousnoreply@blogger.com